press-banner
press
Released date: April 4, 2017

BioXcel Presents Promising Data Demonstrating BXCL701 / Anti-PD1 Combination Increases Anti-Tumor Cytokines and Tumor Growth Inhibition at 2017 AACR Annual Meeting

Next-Generation Small Molecule Checkpoint Inhibitor Targeting Castration-Resistant Prostate Cancer
BRANFORD, CT., April 3, 2017 – BioXcel, a biopharmaceutical company integrating big data analytics and machine learning-based artificial intelligence (AI) with drug development expertise to advance the next wave of medicines, Read More

press
Released date: January 5, 2017

BioXcel Appoints Eric K. Rowinsky, M.D. to its Board of Directors

Appointment of industry leader brings broad R&D Experience to Board
BRANFORD, Conn., Jan. 05, 2017 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial intelligence (AI) with drug development Read More

press
Released date: October 12, 2016

BioXcel Appoints Dr. Peter Mueller as Chairman of Scientific Advisory Board

SAB to Guide Advancement of Multiple Therapeutic Programs

BRANFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced the appointment of Dr. Peter Mueller, Ph.D. as Chairman of its Scientific Read More

press
Released date: September 13, 2016

BioXcel’s BXCL101, Receives Orphan Drug Designation from the U.S. FDA for the Treatment of Patients with Neurofibromatosis Type 2 (NF2)

First therapeutic candidate to emerge from Company’s R&D Engine to be granted Orphan Drug Designation


BRANFORD, Conn., Sept. 13, 2016 (GLOBE NEWSWIRE) — BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced that the U. S. Read More

press
Released date: June 10, 2016

“Impossible is not a declaration. It’s a dare. Impossible is potential. Impossible is temporary.” Muhammad Ali

Muhammad Ali was the epitome of greatness by achieving the impossible in the ring, where he fought against all odds emerging a true champion, but his toughest battle was outside the ring against an opponent that lasted longer than his Read More

press
Released date: May 24, 2016

BioXcel Begins Strategic Collaboration with Alnylam to Discover Novel RNAi Therapeutic Products

Partnership to Harness the Power of BioXcel’s Big Data Innovation Lab
BRANFORD, Conn., May 24, 2016 (GLOBE NEWSWIRE) — BioXcel Corporation, a global leader in real-time big data platforms for the discovery and development of transformative patient treatments, today announced Read More

press
Released date: April 27, 2016

BioXcel to Present at the 3rd International Conference on the Progress of Regenerative Medicine and its Cultural Impact at the Vatican

Presentation to showcase big data’s impact on drug discovery & development

BRANFORD, Conn., April 27, 2016 (GLOBE NEWSWIRE) — BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced that Dr. Read More

press
Released date: March 30, 2016

The Thinking Algorithm

What is it that frightens you? Is it the fear of the unknown? Or its the fear of accepting your destiny?Are you the Neo to Morpheus, not ready to accept your role? Are you Luke to Darth Vader when you Read More

press
Released date: February 19, 2016

BioXcel Celebrates 10th Anniversary as Leader of Big Data Revolution in Healthcare

Steadfast Commitment to Innovation and the Development of Novel Therapeutics
GURGAON, India, Feb. 19, 2016  — BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, and its Gurgaon-based subsidiary and Integrated Center of Read More

press
Released date: February 8, 2016

BioXcel Expands into CNS Orphan Disease Therapeutics

– Novel approach for treatment of rare and ultra-rare CNS diseases-
BRANFORD, Connecticut, February 08, 2016 — BioXcel Corporation, a global leader in cloud-based big data platforms and developer of transformative patient treatments, today announced its expansion into CNS Orphan Read More